Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tumor heterogeneity: morphological, molecular and clinical implications
Autore:
Lleonart, ME; Martin-Duque, P; Sanchez-Prieto, R; Moreno, A; Cajal, SRY;
Indirizzi:
Clin Puerto Hierro, Dept Pathol, Madrid, Spain Clin Puerto Hierro MadridSpain erto Hierro, Dept Pathol, Madrid, Spain
Titolo Testata:
HISTOLOGY AND HISTOPATHOLOGY
fascicolo: 3, volume: 15, anno: 2000,
pagine: 881 - 898
SICI:
0213-3911(200007)15:3<881:THMMAC>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
WILD-TYPE P53; BREAST-CANCER-CELLS; DNA-DAMAGING AGENTS; METASTATIC COLORECTAL CARCINOMAS; HER-2/NEU GENE-EXPRESSION; CYCLIN-DEPENDENT KINASES; P-GLYCOPROTEIN GENE; ADENOVIRUS E1A GENE; IN-VIVO; MULTIDRUG RESISTANCE;
Keywords:
review; tumor; heterogeneity; radioresistance; carcinogenesis;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
215
Recensione:
Indirizzi per estratti:
Indirizzo: Cajal, SRY Clin Puerto Hierro, Dept Pathol, C San Martin Porres 4, Madrid,Spain Clin Puerto Hierro C San Martin Porres 4 Madrid Spain , Spain
Citazione:
M.E. Lleonart et al., "Tumor heterogeneity: morphological, molecular and clinical implications", HIST HISTOP, 15(3), 2000, pp. 881-898

Abstract

Malignant tumors are characterized by their great heterogeneity and variability. There are hundreds of different types of malignant tumors that harbour many oncogenic alterations. The tumor heterogeneity has important morphological, molecular and clinical implications. Except for some hematopoieticand lymphoproliferative processes and small cell infant tumors, there are not specific molecular alterations for most human tumors. In this review wesummarize the most important aspects of carcinogenesis and chemo-radiosensitivity of malignant cells. In this regard, some oncogenes such as neu, rasand bcl-2 have been associated with cellular resistance to treatment with anticancer agents. The knowledge of oncogenic alterations involved in each tumor can be important to correlate the morphological features, the geneticbackground, the prognosis and the clinical response to treatment with anticancer agents. Based on the molecular background of the tumor there are newcancer gene therapy protocols. For example using adenovirus E1a in tumors with overexpression of neu oncogene, inhibitors of tirosine kinase specificfor the PDGF receptor in glioma, inhibitors of farnesil transferase to prevent ras activity in tumors with mutations in the ras gene.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 20:11:43